Qtron Investments LLC Acquires 530 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Qtron Investments LLC increased its stake in Regeneron Pharmaceuticals by 37.5%, owning nearly $1.23 million worth of shares after acquiring additional stock during the first quarter.
• A variety of institutional investors, including Vanguard Group and Goldman Sachs, have also boosted their holdings in Regeneron, with institutional ownership now at 83.31% of the company's stock.
• Regeneron reported a 12.89 EPS for the last quarter, beating analysts' expectations and reflecting a 3.6% year-over-year revenue increase. The company has announced a quarterly dividend of $0.88 per share.

Qtron Investments LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 37.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,945 shares of the biopharmaceutical company's stock after acquiring an additional 530 shares during the period. Qtron Investments LLC's holdings in Regeneron Pharmaceuticals were worth $1,234,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in REGN. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. raised its position in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the period. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Tompkins Financial Corp purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $32,000. Finally, Curat Global LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $32,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 1.5%

Shares of NASDAQ:REGN traded down $8.68 during trading on Friday, reaching $589.48. 1,438,624 shares of the company were exchanged, compared to its average volume of 992,485. The firm has a market capitalization of $62.48 billion, a PE ratio of 14.86, a P/E/G ratio of 1.99 and a beta of 0.33. The business's fifty day simple moving average is $550.48 and its 200-day simple moving average is $592.20. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the company posted $11.56 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on REGN shares. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Citigroup reissued a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Finally, Royal Bank Of Canada increased their price objective on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research report on Monday, August 4th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $829.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.